Core Viewpoint - BridgeBio Pharma is competing with Pfizer and Alnylam Pharmaceuticals in the heart disease treatment market, claiming its drug is more effective and cost-efficient while accusing competitors of using "controversial strategies" [1][2]. Group 1: Competition Overview - The competition centers around the treatment of ATTR cardiomyopathy, which has significant market potential, attracting both large pharmaceutical companies and innovative startups [2]. - Pfizer's drug Vyndamax, approved in 2019, is projected to generate approximately $6.6 billion in revenue this year [2]. - BridgeBio's drug Attruby is expected to surpass $300 million in sales this year, with projections of reaching $2.1 billion by 2030 [3]. Group 2: Claims and Counterclaims - BridgeBio's CEO Neil Kumar criticized Pfizer's presentation of data as unfair, comparing it to contrasting the best performance of one runner with the worst of another [1][2]. - Pfizer responded to accusations regarding misleading information, claiming the video in question was a "misplay" and asserting that their data presentation is accurate [2][3]. Group 3: Regulatory and Market Dynamics - The FDA's Office of Prescription Drug Promotion (OPDP) oversees drug advertising, but it often only becomes aware of issues through complaints from competitors or doctors [5]. - There are concerns about OPDP's capacity to handle complaints due to significant staff reductions earlier this year [5]. Group 4: Research and Data Presentation - Kumar expressed dissatisfaction with a study published in the New England Journal of Medicine regarding Alnylam's drug Amvuttra, arguing that the data presented was adjusted in a misleading way [6]. - Alnylam's research head defended the adjustments made to the data, stating they were intended to clarify drug efficacy [7].

Core Insights - Alnylam Pharmaceuticals is a commercial-stage company with four marketed drugs, including Amvuttra, which is its primary revenue driver, generating $801.9 million in sales in the first half of 2025, reflecting an 89% year-over-year growth [2][10] - Amvuttra received label expansion approvals in the U.S. and EU for treating ATTR amyloidosis with cardiomyopathy, marking it as the first RNAi therapeutic approved for both ATTR-CM and hATTR-PN in adults [3][4] - Alnylam's stock has surged 93% in 2025, outperforming the industry and S&P 500, although the stock is considered expensive with a price/sales ratio of 24.10 compared to the industry average of 2.12 [8][12] Drug Performance - Amvuttra's sales growth is attributed to new patient starts and patients switching from Onpattro, with expectations for continued growth following the recent label expansion [2][4] - The label expansion is anticipated to further boost Amvuttra's uptake in the second half of 2025, with additional approvals expected in other regions [4] Competitive Landscape - Amvuttra faces competition from Pfizer's Vyndaqel/Vyndamax and BridgeBio's Attruby, which are already approved for ATTR-CM and offer advantages such as oral administration and lower list prices [5] - Pfizer's Vyndaqel family generated $3.1 billion in global revenues in the first half of 2025, a 27% increase year-over-year, indicating strong market demand [6] Financial Estimates - Alnylam's earnings estimates for 2025 have improved significantly, with projections rising from 93 cents to $3.39 per share, and for 2026 from $3.58 to $8.75 [15]